Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction‐associated steatotic liver disease: A multicentre study
Imeglimin efficaciously improved liver inflammation and fibrosis in patients with T2D and MASLD, with no significant changes in liver fat content or stiffness. These findings suggest that imeglimin is a promising therapeutic drug for the management of MASLD in the context of T2D, warranting further research on its long-term efficacy and mechanisms of action.
Authors
- Koji Fujita (ORCID: https://orcid.org/0000-0003-3753-4981)
- Tomoko Tadokoro (ORCID: https://orcid.org/0000-0001-9975-386X)
- Hideki Kobara (ORCID: https://orcid.org/0000-0002-8508-827X)
- Mai Nakahara
- Takafumi Yoshimura
- Joji Tani (ORCID: https://orcid.org/0000-0001-8801-2505)
- Hitomi Imachi
- Toshihiro Kobayashi
- Takanobu Saheki
- Koji Murao (ORCID: https://orcid.org/0000-0002-7335-7196)
- Seisuke Sato
- Kyoko Oura (ORCID: https://orcid.org/0000-0002-9531-7240)
- Kensaku Fukunaga (ORCID: https://orcid.org/0000-0002-0012-5263)
- K. Komori
- Asahiro Morishita
Institutions
- Kagawa University (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1111/dom.16157
- Citations
- 4
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.55